LABFF (Laboratorios Farmaceuticos Rovi) Momentum Rank: 9 (As of Aug. 25, 2026) — 125% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LABFF Laboratorios Farmaceuticos Rovi SA LABFF
99 GF Score
Price $67.17
GF Value $85.89
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Momentum Rank?

Laboratorios Farmaceuticos Rovi LABFF 99 Momentum Rank is 9 as of Aug. 25, 2026, which is 125% above its 10-year median of 4.00. GuruFocus rates LABFF with a GF Score™ of 99/100 and a GF Value™ of $85.89 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Laboratorios Farmaceuticos Rovi has the Momentum Rank of 9.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Laboratorios Farmaceuticos Rovi Momentum Rank Related Terms

LABFF vs ZTS, UTHR, VTRS: Momentum Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi Momentum Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Momentum Rank falls into.


LABFF
99GF Score
Laboratorios Farmaceuticos Rovi SA LABFF
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 9 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Momentum Rank of 9 as of Aug. 25, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 125% above median its historical median of 4.00. Over the past decade, Laboratorios Farmaceuticos Rovi's Momentum Rank has ranged from 1.00 to 10.00.
Is Laboratorios Farmaceuticos Rovi's Momentum Rank too high?
Laboratorios Farmaceuticos Rovi's current Momentum Rank of 9 is 125% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Momentum Rank compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Momentum Rank of 9 can be compared against companies in the Drug Manufacturers industry. Historically, Laboratorios Farmaceuticos Rovi's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Drug Manufacturers company?
A good Momentum Rank depends on the Drug Manufacturers industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Momentum Rank is 9, which is 125% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (LABFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.89, compared to a current price of $67.17 — trading 21.8% below its estimated fair value. The current Momentum Rank is 9, which is 125% above median its 10-year median of 4.00. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Momentum Rank is 9 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be undervalued. The current stock price of $67.17 is trading 21.8% below its estimated GF Value™ of $85.89. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Undervalued.

Key valuation signals for LABFF:

  • Momentum Rank: 9 (125% above median its 10-year median of 4.00)
  • GF Value™: $85.89 vs. price of $67.17 (21.8% below fair value)
  • GF Score™: 99/100 with 2 warning signs

No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
99GF Score

Get the complete analysis for LABFF

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.17
Price
$85.89
GF Value